CORE-001
60 evidence topics · 16 sources
Objective
Study purpose in the ClinicalTrials.gov record
Study question in the published final results
Primary and secondary objectives in the clinical study protocol
Expected benefit of the combination in the clinical study protocol
Location and study date
Study dates, enrollment, and sites in the ClinicalTrials.gov record
| Study characteristic | Quoted record |
|---|---|
| Study start (actual) | “2020-12-08” |
| Primary completion (actual) | “2023-03-07” |
| Study completion (actual) | “2024-05-28” |
| Enrollment (actual) | “35” |
| Sites | “This study has 19 locations” |
Enrollment by country in the published final results
| Country | Participants, n (%) |
|---|---|
| USA | “30 (85.7)” |
| Korea | “5 (14.3)” |
Planned accrual period and end of long-term follow-up in the clinical study protocol
Data cutoffs for the final results
Publication and congress presentation of the final results
Study design
Single-arm, open-label design in the ClinicalTrials.gov record
| Design characteristic | Quoted record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Collaborator | “Merck Sharp & Dohme LLC” |
Design overview and safety lead-in cohort in the clinical study protocol
Disease assessments and central review in the clinical study protocol
Trial design and Merck supply agreement in the annual report
Eligibility criteria
Key inclusion criteria in the clinical study protocol
Key exclusion criteria in the clinical study protocol
Definition of BCG-unresponsive disease and the 15-month assessment window in the ClinicalTrials.gov record
FDA guidance as the basis of the BCG-unresponsive definition in the clinical study protocol
Treatment
Treatment schedule in the published final results
Cretostimogene dose and schedule in the clinical study protocol
Bladder wash and instillation procedure with DDM in the clinical study protocol
Pembrolizumab dose and transition from every-3-week dosing in the clinical study protocol
Treatment arm in the ClinicalTrials.gov record
Dose concentration and dosing schedule in the annual report
Study outcomes
Rationale for using complete response at 12 months as the primary endpoint
Primary and secondary endpoints in the published final results
Mandatory bladder mapping at 12 months in the clinical study protocol
Definition of complete response in the clinical study protocol
Historical 12-month complete response rates cited as the basis for the null hypothesis in the clinical study protocol
Complete response rate with duration of response as the single-arm endpoint in FDA guidance
Clinically meaningful durable response rate at 12 months in International Bladder Cancer Group recommendations
Secondary endpoints in the clinical study protocol
“Complete response rate at any time” (opens the source at this quote in a new tab)
“Duration of response” (opens the source at this quote in a new tab)
“Cystectomy free survival” (opens the source at this quote in a new tab)
“Progression free survival” (opens the source at this quote in a new tab)
“Overall survival” (opens the source at this quote in a new tab)
Exploratory endpoints including viral shedding in the clinical study protocol
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation in the clinical study protocol
Target and actual enrollment in the ClinicalTrials.gov record
Participants treated and analyzed in the published final results
Description of analysis sets
Analysis populations in the clinical study protocol
Handling of participants without a 12-month assessment and time-to-event methods in the clinical study protocol
Safety analysis methods in the clinical study protocol
Evaluable-patient denominators in the annual report
Results
Participant disposition
Reasons for discontinuation without disease recurrence
Reasons for screen failure
Baseline characteristics
Baseline characteristics in the published final results
| Characteristic | n = 35 |
|---|---|
| Age, median | “72” |
| Age, range | “57–90” |
| Sex, male | “33 (94.3)” |
| Sex, female | “2 (5.7)” |
| ECOG 0 | “25 (71.4)” |
| ECOG 1 | “9 (25.7)” |
| ECOG 2 | “1 (2.9)” |
| Race, White | “27 (77.1)” |
| Race, Black/African American | “2 (5.7)” |
| Race, Asian | “5 (14.3)” |
| Race, unknown | “1 (2.9)” |
| Stage, CIS | “27 (77.1)” |
| Stage, CIS + high-grade Ta | “4 (11.4)” |
| Stage, CIS + high-grade T1 | “4 (11.4)” |
| Prior BCG courses, 2 | “18 (51.4)” |
| Prior BCG courses, 3 | “8 (22.9)” |
| Prior BCG courses, 4 | “2 (5.7)” |
| Prior BCG courses, 5 | “4 (11.4)” |
| Prior BCG courses, ≥6 | “3 (8.6)” |
Prior BCG instillations and persistent or recurrent disease in the interim presentation
| Characteristic | Quoted value |
|---|---|
| Number of prior BCG instillations, median (range) | “12 (9 - 30)” |
| Persistent high-risk NMIBC, n | “21” |
| Persistent high-risk NMIBC, % | “60” |
| Recurrent high-risk NMIBC, n | “14” |
| Recurrent high-risk NMIBC, % | “40” |
Participants enrolled at U.S. sites in a pooled demographic analysis
Efficacy results
Complete response at 12 months, 3 months, and 24 months in the published final results
Final results at the May 17, 2024 data cutoff: response durability, Kaplan-Meier estimates, progression-free and cystectomy-free survival
Complete response at any time, 12 months, and 24 months in the annual report
Correction to the key of the duration-of-response figure
Exploratory urinary minimal residual disease analysis across BOND-003 and CORE-001
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related adverse events in the published final results
Treatment-related adverse effects by maximum severity
| Preferred term | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) | Total (N = 35), n (%) |
|---|---|---|---|---|
| Participants with at least one study drug-related treatment-emergent adverse effect | “9 (25.7)” | “18 (51.4)” | “5 (14.3)” | “32 (91.4)” |
| Bladder spasm | “13 (37.1)” | “4 (11.4)” | “0” | “17 (48.6)” |
| Fatigue | “11 (31.4)” | “2 (5.7)” | “0” | “13 (37.1)” |
| Dysuria | “8 (22.9)” | “1 (2.9)” | “0” | “9 (25.7)” |
| Pollakiuria | “8 (22.9)” | “1 (2.9)” | “0” | “9 (25.7)” |
| Hematuria | “5 (14.3)” | “1 (2.9)” | “0” | “6 (17.1)” |
| Micturition urgency | “4 (11.4)” | “2 (5.7)” | “0” | “6 (17.1)” |
| Diarrhea | “4 (11.4)” | “0” | “1 (2.9)” | “5 (14.3)” |
| Nocturia | “3 (8.6)” | “1 (2.9)” | “0” | “4 (11.4)” |
| Hypothyroidism | “1 (2.9)” | “3 (8.6)” | “0” | “4 (11.4)” |
| Urinary tract infection | “3 (8.6)” | “1 (2.9)” | “0” | “4 (11.4)” |
| Blood alkaline phosphatase increased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Ejection fraction decreased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Neutrophil count decreased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Adrenal insufficiency | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Immune-mediated hepatitis | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
Attribution of grade 3 or higher events and table inclusion rules
Author correction removing attribution of immune-related adverse effects from the abstract
“…all related to pembrolizumab” (opens the source at this quote in a new tab)
“has been removed from the Abstract.” (opens the source at this quote in a new tab)
“assessed by the treating physicians” (opens the source at this quote in a new tab)
“Related adverse effect to pembrolizumab…” (opens the source at this quote in a new tab)
Safety summary in the annual report
Grade 3 events and absence of grade 4 or 5 events in the interim presentation
“Grade 3 AE included (4 total patients)” (opens the source at this quote in a new tab)
“Autoimmune hepatitis” (opens the source at this quote in a new tab)
“Reduced ejection fraction” (opens the source at this quote in a new tab)
“Neutrophil count decreased” (opens the source at this quote in a new tab)
“Alkaline phosphatase increased” (opens the source at this quote in a new tab)
“Adrenal insufficiency” (opens the source at this quote in a new tab)
“Grade 4 / 5 AE – none observed” (opens the source at this quote in a new tab)
Adverse event grading and serious adverse event capture in the clinical study protocol
Study limitations
Summary
CORE-001 was a single-arm, open-label phase 2 trial of 35 participants with no control arm, so the contribution of cretostimogene to the combination cannot be separated from that of pembrolizumab within the trial. The protocol tested a 12-month complete response rate of 19% (H0) against 36% (Ha) at a one-sided alpha of 0.10 with approximately 81% power, and required 30 evaluable participants. The 12-month complete response rate was 57.1% (20 of 35; 95% CI 40.7% to 73.5% in the publication and 39.5% to 73.2% in the annual report). The 24-month complete response rate was 51.4% (18 of 35) in the publication and 54% (19 of 35) at the later May 17, 2024 data cutoff reported by the company. Long-term efficacy and survival follow-up stopped under Protocol Amendment 7, so data beyond 24 months were not collected. Thirty of 35 participants (85.7%) were enrolled in the USA and 5 (14.3%) in Korea; 33 (94.3%) were male. Pembrolizumab dosing changed during the trial from 200 mg every 3 weeks to 400 mg every 6 weeks, and the DDM concentration is described as 5% in the protocol synopsis and registry record and as 0.1% in the protocol administration procedure. An author correction removed the abstract statements that attributed immune-related adverse effects exclusively to pembrolizumab, and added that attribution of adverse effects to pembrolizumab was “assessed by the treating physicians”. Long-term follow-up assessments were based on local review.